Brain Disease-Modifying Effects of Radiofrequency as a Non-Contact Neuronal Stimulation Technology.

Accumulating evidence suggests that exposure to radiofrequency electromagnetic fields (RF-EMF) can affect key physiological and cognitive processes, including neuronal excitability, glucose metabolism, sleep architecture, and even systemic metabolic regulation. These complex interactions have been demonstrated in vitro, in animal models, and in human trials. RF-EMF has been shown to enhance and impair brain function. For example, it reduces amyloid-β secretion and plaque formation in Alzheimer’s models, but it can also induce oxidative stress and apoptotic signaling under certain conditions. This review summarizes recent findings on RF-EMF-mediated neurostimulation and its potential therapeutic applications for neurodegenerative diseases, such as Alzheimer’s.

This narrative review compiles peer-reviewed studies published between 2000 and 2025. These studies include cellular assays, transgenic rodent models of Alzheimer’s disease, and clinical investigations in humans. Although a formal systematic search protocol was lacking, the authors prioritized studies that specified exposure parameters, such as precise SAR values and carrier frequencies, to facilitate comparability. The main focus of the included studies was neurodegenerative pathologies, particularly Alzheimer’s disease. A total of 57 studies were evaluated, 34 (60%) of which employed non-thermal SAR thresholds (≤ 2 W/kg).

Of the 57 studies surveyed, 81% reported measurable biological effects of RF-EMF, while 19% found no significant outcomes. Among the studies employing non-thermal SAR thresholds, 88% observed modulation of neurophysiological endpoints, regardless of whether the effect was beneficial or detrimental. Animal models frequently showed reductions in amyloid-β load and reactive oxygen species, accompanied by improvements in spatial memory and synaptic plasticity. Conversely, certain in vitro and human EEG studies documented increased oxidative stress markers, apoptotic cell death, and altered sleep patterns. Clinical trials often revealed subtle changes in EEG spectral power and sleep latency. Biological effects such as improved declarative memory have been observed even at SAR levels as low as 6.4 mW/kg.

According to the authors, the balance of evidence indicates that RF-EMF can act as a non-contact neuromodulator capable of both ameliorating and exacerbating neurodegenerative pathology, depending on exposure parameters. While preclinical models provide compelling data on Alzheimer’s-related endpoints, the heterogeneity of study designs and the absence of large-scale, randomized clinical trials prevent definitive risk–benefit assessments. Thus, rigorous, standardized investigations are essential to determine optimal frequencies, intensities, and modulation schemes for therapeutic neuromodulation.

Editor's note:

Nevertheless, or precisely because of its medical approach, the publication indicates that non-thermal, biological effects of radiofrequency electromagnetic fields exist. However, its narrative approach and lack of systematic inclusion criteria limit quantitative synthesis and meta-analytic rigor. This study is not a systematic review or meta-analysis. Rather, the authors aimed to test the hypothesis that radio frequencies are effective for neural stimulation in a therapeutic context. The study was not intended to evaluate the risks associated with radiofrequency electromagnetic fields. Nevertheless, the concept of contact-free brain stimulation is an emerging field that warrants further exploration, particularly in the context of dementia treatment. (RH)